Go to
current issue
-
A future for regulatory science in the European Union: the European Medicines Agency’s strategy Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-31 Philip A. Hines; Rosanne Janssens; Rosa Gonzalez-Quevedo; Apolline I.O.M. Lambert; Anthony J. Humphreys
After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency’s Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.
-
Boost for base editing to treat inherited blood disorders Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-31 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
The small-cell lung cancer drug market Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-31 Joshua B. N. Dawkins; Rachel M. Webster
Discover the world’s best science and medicine | Nature.com
-
Macrophages get a CAR Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-30 M. Teresa Villanueva
Discover the world’s best science and medicine | Nature.com
-
Advances in therapeutic peptides targeting G protein-coupled receptors Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-19 Anthony P. Davenport; Conor C. G. Scully; Chris de Graaf; Alastair J. H. Brown; Janet J. Maguire
-
Ted W. Love Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-16 Asher Mullard
In 2013, Ted W. Love — a former drug developer at Onyx, Genentech and elsewhere and cardiologist by training — came out of retirement to take on sickle cell disease. This inherited blood disorder, in which sickled red blood cells clump together, blocking blood flow and the delivery of oxygen through the body, afflicts nearly 100,000 people in the USA and millions more throughout the world. And yet
-
Upcoming market catalysts in Q2 2020 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-16 Elaf Elkadi
Discover the world’s best science and medicine | Nature.com
-
Author Correction: Next-generation influenza vaccines: opportunities and challenges Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-13 Chih-Jen Wei; Michelle C. Crank; John Shiver; Barney S. Graham; John R. Mascola; Gary J. Nabel
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Top companies and drugs by sales in 2019 Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-13 Lisa Urquhart
Discover the world’s best science and medicine | Nature.com
-
Blocking endocytosis gives therapeutic antibodies a boost Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-11 Katharine H. Wrighton
Discover the world’s best science and medicine | Nature.com
-
Small molecule reduces epileptic seizures in mice Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-11 M. Teresa Villanueva
Discover the world’s best science and medicine | Nature.com
-
Tapping the therapeutic potential of the innate immune system Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-10 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Targeting CAR T cells to glioblastoma Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-09 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Inhibiting peptidoglycan remodelling Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-09 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Predicting novel antibacterial agents Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-09 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Combination treatment stimulates β-cell proliferation Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-09 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Monitoring protein communities and their responses to therapeutics Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-05 Hanna G. Budayeva; Donald S. Kirkpatrick
-
Therapeutic strategies for thrombosis: new targets and approaches Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-04 Nigel Mackman; Wolfgang Bergmeier; George A. Stouffer; Jeffrey I. Weitz
-
Exploiting proteome instability to enhance immunotherapy Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-03-03 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Antimicrobial host defence peptides: functions and clinical potential. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-27 Neeloffer Mookherjee,Marilyn A Anderson,Henk P Haagsman,Donald J Davidson
-
Opportunities and challenges with microphysiological systems: a pharma end-user perspective Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-24 Lorna Ewart; Adrian Roth
Using human-relevant, translational in vitro models is widely considered to reduce attrition during drug discovery and development. Despite this, the adoption of models based on microphysiological systems — organs-on-chips or organoids — by pharma companies is moderate at best, and realizing the full potential of these models will need greater collaboration between stakeholders.
-
GPR84: an immune response dial? Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-20 Megan L. Wojciechowicz; Avi Ma’ayan
Discover the world’s best science and medicine | Nature.com
-
Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-14 Chih-Jen Wei,Michelle C Crank,John Shiver,Barney S Graham,John R Mascola,Gary J Nabel
-
Reducing α-synuclein accumulation. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-11 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Epigenetic therapy prevents AML. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-11 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Shocking HIV out of hiding. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-11 Alexandra Flemming
Discover the world’s best science and medicine | Nature.com
-
Reversing inflammaging. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-11 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
GPCR agonist targets obesity and diabetes. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-11 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Double boost for cancer cell therapy. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-10 Megan Cully
Discover the world’s best science and medicine | Nature.com
-
Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-10 Guangdi Li,Erik De Clercq
Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV, some of which are already moving into clinical trials.
-
Dual-acting peptide tackles triglycerides. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-07 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Sandra Horning. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-30 Asher Mullard
Roche is the world’s top oncology company by sales, earning nearly US$28 billion in 2018 just from its anticancer drugs. And oncologist Sandra Horning has been instrumental in making that possible, shaping the company’s development priorities for the past decade. An oncologist by training, Horning served as Global Head of Clinical Science for Oncology and Hematology at Genentech/Roche from 2009 to
-
Tumour-agnostic therapies Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-28 Ann-Marie Looney; Khurram Nawaz; Rachel M. Webster
Discover the world’s best science and medicine | Nature.com
-
Widening the window of bromodomain inhibition. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-23 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
ASPI: a public–private partnership to develop treatments for autism Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-22 Seth Ness; Gahan Pandina; Shyla Jagannatha; Kyle Wathen; Abigail Bangerter; Nikolay V. Manyakov; Robert Hendren; Bennett Leventhal; Declan Murphy; Geraldine Dawson; Wayne C. Drevets; Husseini K. Manji
Numerous potential therapeutic targets are being investigated in autism spectrum disorder (ASD). Here, we discuss a platform trial approach for designing proof-of-concept (POC) clinical studies of ASD — via the Autism Spectrum POC Initiative (ASPI) — that can be conducted through a public–private partnership with the aim of finding effective treatments in the most expeditious manner.
-
Neutrophils as emerging therapeutic targets. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-22 Tamás Németh,Markus Sperandio,Attila Mócsai
-
Top product forecasts for 2020. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Lisa Urquhart
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: Breast cancer drug approvals by the US FDA from 1949 to 2018. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-14 Chandra P Leo,Cornelia Leo,Thomas D Szucs
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Sorafenib analogue combats MRSA. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Improving immunotherapy. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Hydrogel fights infection and inflammation. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Saving hearts with HDAC inhibition. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Driving CARs to last. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Megan Cully
Discover the world’s best science and medicine | Nature.com
-
bnAbs for HIV: shepherding towards improbable mutations. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Alexandra Flemming
Discover the world’s best science and medicine | Nature.com
-
Biopharma dealmaking in 2019. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Amanda Micklus,Patricia Giglio
Discover the world’s best science and medicine | Nature.com
-
Restoring FGF21 reverses pancreatitis. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
-
Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-08 Erik Tambuyzer,Benjamin Vandendriessche,Christopher P Austin,Philip J Brooks,Kristina Larsson,Katherine I Miller Needleman,James Valentine,Kay Davies,Stephen C Groft,Robert Preti,Tudor I Oprea,Marco Prunotto
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-08 Gregory C Fanning,Fabien Zoulim,Jinlin Hou,Antonio Bertoletti
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Value of 2019 FDA approvals: back to the recent average. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-02-01 Mathias Baedeker,Michael Ringel,Ulrik Schulze
Discover the world’s best science and medicine | Nature.com
-
NK cells for cancer immunotherapy. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-06 Noriko Shimasaki,Amit Jain,Dario Campana
-
'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-03 S Depil,P Duchateau,S A Grupp,G Mufti,L Poirot
-
Advances in oral peptide therapeutics. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-17 Daniel J Drucker
-
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-13 Erik Tambuyzer,Benjamin Vandendriessche,Christopher P Austin,Philip J Brooks,Kristina Larsson,Katherine I Miller Needleman,James Valentine,Kay Davies,Stephen C Groft,Robert Preti,Tudor I Oprea,Marco Prunotto
-
Andy Plump. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-01 Asher Mullard
With Takeda’s US$62 billion acquisition of Shire in 2018, the Japanese firm scored a spot as a top 10 pharmaceutical firm. But well before the deal was even on the radar, President of R&D Andy Plump and CEO Christophe Weber were already working to transform the company. Once a small-molecule specialist, it is now embracing new modalities to be better positioned to follow the biology of disease. Once
-
Upcoming market catalysts in Q1 2020. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-01 Jenny Tan
Discover the world’s best science and medicine | Nature.com
-
Sickle cell disease celebration. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-01 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
RNAi agents score an approval and drive an acquisition. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-01 Asher Mullard
Discover the world’s best science and medicine | Nature.com
-
Rethinking drug design in the artificial intelligence era Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2019-12-04 Petra Schneider, W. Patrick Walters, Alleyn T. Plowright, Norman Sieroka, Jennifer Listgarten, Robert A. Goodnow, Jasmin Fisher, Johanna M. Jansen, José S. Duca, Thomas S. Rush, Matthias Zentgraf, John Edward Hill, Elizabeth Krutoholow, Matthias Kohler, Jeff Blaney, Kimito Funatsu, Chris Luebkemann, Gisbert Schneider
-
Learning from worms to kill Gram-negative bacteria. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-01 Stacey-Lynn Paiva
Discover the world’s best science and medicine | Nature.com
-
Decoy receptor targets lung cancer. Nat. Rev. Drug. Disc. (IF 57.618) Pub Date : 2020-01-01 Sarah Crunkhorn
Discover the world’s best science and medicine | Nature.com
京公网安备 11010802027423号